Literature DB >> 21844013

Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism.

Melissa A Fath1, Iman M Ahmad, Carmen J Smith, Jacquelyn Spence, Douglas R Spitz.   

Abstract

PURPOSE: Cancer cells (relative to normal cells) show increased steady-state levels of hydroperoxides that are compensated by increased glucose and hydroperoxide metabolism. The current study determined whether inhibitors of glucose and hydroperoxide metabolism could induce chemoradiosensitization by enhancing oxidative stress in lung cancer cells. EXPERIMENTAL
DESIGN: A549 and NCI-H292 human lung carcinoma cells were treated with 2-deoxy-d-glucose (2DG) combined with carboplatin + ionizing radiation (IR). Lung cancer cells were further sensitized with inhibitors of glutathione (GSH)- and thioredoxin (Trx)-dependent metabolism [buthionine sulfoximine (BSO) and auranofin, respectively] in vitro and in vivo.
RESULTS: When 2DG was combined with carboplatin + IR, clonogenic cell killing was enhanced in A549 and NCI-H292 cells, and this combination was more effective than paclitaxel + carboplatin + IR. The thiol antioxidant (N-acetylcysteine, NAC) was capable of protecting cancer cells from 2DG + carboplatin -induced cell killing. Simultaneous treatment of cancer cells with BSO and auranofin, at doses that were not toxic as single agents, also enhanced lung cancer cell killing and sensitivity to 2DG + carboplatin. This treatment combination also increased oxidation of both GSH and Trx, which were inhibited by NAC. Mice treated with auranofin + BSO showed no alterations in circulating leukocytes or red blood cells. Xenograft lung tumor growth in mice was more effectively inhibited by treatment with auranofin + BSO + carboplatin than animals treated with carboplatin or auranofin + BSO alone.
CONCLUSIONS: These results show in vitro and in vivo that simultaneous inhibition of GSH and Trx metabolism can effectively inhibit lung cancer cell growth and induce chemosensitization by a mechanism that involves thiol-mediated oxidative stress. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844013      PMCID: PMC3186854          DOI: 10.1158/1078-0432.CCR-11-0736

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells.

Authors:  Xiaofei Wang; Evelyn Perez; Ran Liu; Liang-Jun Yan; Robert T Mallet; Shao-Hua Yang
Journal:  Brain Res       Date:  2006-12-15       Impact factor: 3.252

2.  Acute toxicity and cardio-respiratory effects of 2-deoxy-D-glucose: a promising radio sensitiser.

Authors:  R Vijayaraghavan; Deo Kumar; S N Dube; R Singh; K S Pandey; B C Bag; M P Kaushik; K Sekhar; B S Dwarakanath; T Ravindranath
Journal:  Biomed Environ Sci       Date:  2006-04       Impact factor: 3.118

3.  2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells.

Authors:  Andrean L Simons; Iman M Ahmad; David M Mattson; Kenneth J Dornfeld; Douglas R Spitz
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

4.  Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells.

Authors:  Iman M Ahmad; Nukhet Aykin-Burns; Julia E Sim; Susan A Walsh; Ryuji Higashikubo; Garry R Buettner; Sujatha Venkataraman; Michael A Mackey; Shawn W Flanagan; Larry W Oberley; Douglas R Spitz
Journal:  J Biol Chem       Date:  2004-11-23       Impact factor: 5.157

5.  Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.

Authors:  Christine Marzano; Valentina Gandin; Alessandra Folda; Guido Scutari; Alberto Bindoli; Maria Pia Rigobello
Journal:  Free Radic Biol Med       Date:  2006-12-22       Impact factor: 7.376

Review 6.  Molecular mechanisms of resistance and toxicity associated with platinating agents.

Authors:  Cara A Rabik; M Eileen Dolan
Journal:  Cancer Treat Rev       Date:  2006-11-03       Impact factor: 12.111

7.  Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase.

Authors:  Maria Pia Rigobello; Alessandra Folda; Maria Cristina Baldoin; Guido Scutari; Alberto Bindoli
Journal:  Free Radic Res       Date:  2005-07

8.  Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  James R Jett; Steven E Schild; Robert L Keith; Kenneth A Kesler
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

9.  Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).

Authors:  Yo Omata; Matt Folan; Melissa Shaw; Regina L Messer; Petra E Lockwood; David Hobbs; Serge Bouillaguet; Hidehiko Sano; Jill B Lewis; John C Wataha
Journal:  Toxicol In Vitro       Date:  2006-02-28       Impact factor: 3.500

10.  Pyruvate reduces DNA damage during hypoxia and after reoxygenation in hepatocellular carcinoma cells.

Authors:  Emilie Roudier; Christine Bachelet; Anne Perrin
Journal:  FEBS J       Date:  2007-09-14       Impact factor: 5.542

View more
  54 in total

Review 1.  Manipulation of Glucose and Hydroperoxide Metabolism to Improve Radiation Response.

Authors:  John M Floberg; Julie K Schwarz
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

Review 2.  Selenoproteins: molecular pathways and physiological roles.

Authors:  Vyacheslav M Labunskyy; Dolph L Hatfield; Vadim N Gladyshev
Journal:  Physiol Rev       Date:  2014-07       Impact factor: 37.312

Review 3.  Modulators of Redox Metabolism in Head and Neck Cancer.

Authors:  Xiaofei Chen; Jade Mims; Xiumei Huang; Naveen Singh; Edward Motea; Sarah M Planchon; Muhammad Beg; Allen W Tsang; Mercedes Porosnicu; Melissa L Kemp; David A Boothman; Cristina M Furdui
Journal:  Antioxid Redox Signal       Date:  2017-12-20       Impact factor: 8.401

4.  Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15-18 October 2017; Cancun, Mexico.

Authors:  Kelly C Falls; Ricky A Sharma; Yaacov R Lawrence; Richard A Amos; Sunil J Advani; Mansoor M Ahmed; Bhadrasain Vikram; C Norman Coleman; Pataje G Prasanna
Journal:  Radiat Res       Date:  2018-10       Impact factor: 2.841

5.  Targeting SOD1 reduces experimental non–small-cell lung cancer.

Authors:  Andrea Glasauer; Laura A Sena; Lauren P Diebold; Andrew P Mazar; Navdeep S Chandel
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

Review 6.  Dual targeting of the thioredoxin and glutathione systems in cancer and HIV.

Authors:  Moran Benhar; Iart Luca Shytaj; Jonathan S Stamler; Andrea Savarino
Journal:  J Clin Invest       Date:  2016-05-02       Impact factor: 14.808

7.  Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.

Authors:  Ramachandran Rashmi; Kay Jayachandran; Jin Zhang; Vishnu Menon; Naoshad Muhammad; Michael Zahner; Fiona Ruiz; Sisi Zhang; Kevin Cho; Yuting Wang; Xiaojing Huang; Yi Huang; Michael L McCormick; Buck E Rogers; Douglas R Spitz; Gary J Patti; Julie K Schwarz
Journal:  Mol Cancer Ther       Date:  2020-10-21       Impact factor: 6.261

8.  Metabolic Stress-Induced Phosphorylation of KAP1 Ser473 Blocks Mitochondrial Fusion in Breast Cancer Cells.

Authors:  Chun-Ting Cheng; Ching-Ying Kuo; Ching Ouyang; Chien-Feng Li; Yiyin Chung; David C Chan; Hsing-Jien Kung; David K Ann
Journal:  Cancer Res       Date:  2016-06-30       Impact factor: 12.701

9.  Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells.

Authors:  Marike W van Gisbergen; Marcus Cebula; Jie Zhang; Astrid Ottosson-Wadlund; Ludwig Dubois; Philippe Lambin; Kenneth D Tew; Danyelle M Townsend; Guido R M M Haenen; Marie-José Drittij-Reijnders; Hisao Saneyoshi; Mika Araki; Yuko Shishido; Yoshihiro Ito; Elias S J Arnér; Hiroshi Abe; Ralf Morgenstern; Katarina Johansson
Journal:  Mol Pharm       Date:  2016-04-28       Impact factor: 4.939

10.  Thioredoxin-1 contributes to protection against DON-induced oxidative damage in HepG2 cells.

Authors:  Kei-Ichi Sugiyama; Mawo Kinoshita; Yoichi Kamata; Yuji Minai; Fumito Tani; Yoshiko Sugita-Konishi
Journal:  Mycotoxin Res       Date:  2012-03-16       Impact factor: 3.833

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.